US appeals court affirms invalidity of Ultram ER patent
This article was originally published in Scrip
Executive Summary
A US federal appeals court has affirmed the invalidity of the two patents held by Purdue Pharma relating to once-daily Ultram ER (extended-release tramadol), in a boost for Par Pharmaceutical, which has been marketing a generic tablet version in the 100mg and 200mg strengths since last year.